Evelo Biosciences Valuation
| EVLO Stock | USD 0.0005 0.00 0.00% |
Evelo Biosciences seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Evelo Biosciences from reviewing the firm fundamentals such as Current Valuation of 23.69 M, shares owned by institutions of 83.13 %, and Shares Owned By Insiders of 0.23 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Evelo Biosciences' price fluctuation is out of control at this time. Calculation of the real value of Evelo Biosciences is based on 3 months time horizon. Increasing Evelo Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Evelo Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Evelo Pink Sheet. However, Evelo Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.0E-4 | Real 3.6E-4 | Hype 5.15E-4 | Naive 6.42E-4 |
The intrinsic value of Evelo Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Evelo Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Evelo Biosciences helps investors to forecast how Evelo pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Evelo Biosciences more accurately as focusing exclusively on Evelo Biosciences' fundamentals will not take into account other important factors: Evelo Biosciences Total Value Analysis
Evelo Biosciences is currently expected to have valuation of 23.69 M with market capitalization of 7 M, debt of 51.14 M, and cash on hands of 92.01 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Evelo Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
23.69 M | 7 M | 51.14 M | 92.01 M |
Evelo Biosciences Asset Utilization
One of the ways to look at asset utilization of Evelo is to check how much profit was generated for every dollar of assets it reports. Evelo Biosciences shows a negative utilization of assets of -0.83 percent, losing $0.008325 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Evelo Biosciences shows how discouraging it operates for each dollar spent on its assets.Evelo Biosciences Ownership Allocation
Evelo Biosciences holds a total of 18.93 Million outstanding shares. The majority of Evelo Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Evelo Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Evelo Biosciences. Please pay attention to any change in the institutional holdings of Evelo Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Evelo Biosciences Profitability Analysis
Net Loss for the year was (114.53 M) with profit before overhead, payroll, taxes, and interest of 0.About Evelo Biosciences Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Evelo Biosciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Evelo Biosciences based exclusively on its fundamental and basic technical indicators. By analyzing Evelo Biosciences's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Evelo Biosciences's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Evelo Biosciences. We calculate exposure to Evelo Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Evelo Biosciences's related companies.Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Evelo Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.
8 Steps to conduct Evelo Biosciences' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Evelo Biosciences' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Evelo Biosciences' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Evelo Biosciences' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Evelo Biosciences' revenue streams: Identify Evelo Biosciences' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Evelo Biosciences' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Evelo Biosciences' growth potential: Evaluate Evelo Biosciences' management, business model, and growth potential.
- Determine Evelo Biosciences' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Evelo Biosciences' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Evelo Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.4 M |
Other Information on Investing in Evelo Pink Sheet
Evelo Biosciences financial ratios help investors to determine whether Evelo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evelo with respect to the benefits of owning Evelo Biosciences security.